IONQ Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? IONQ Inc trades at $30.9 (market cap $14.07B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: IONQ Inc is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 34 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| IONQ | KYMR | |
|---|---|---|
Market Cap | $14.07B | $8.87B |
Volume | 23,412,195 | 779,107 |
Sector | Technology | Health |
52-Week High | $72.41 | $127.31 |
52-Week Low | $26.59 | $55.80 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $12.01B | $8.26B |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite recent earnings beats. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a -553% net income margin. Analyst consensus is split with a $65.20 price target suggesting 88% upside potential, while technical indicators show oversold conditions with RSI at 26.86.
The stock presents high-risk, high-reward potential with Wall Street divided on its path to profitability. Key catalysts include quantum technology adoption and manufacturing scaling, while risks center on cash burn and competitive threats in the emerging quantum computing space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →